Novo Nordisk Halts Phase III Concizumab Hemophilia Trials After Three Thrombotic Events
No new patients will be enrolled, and trial participants will stop treatment with the tissue factor pathway inhibitor antibody, a class with four prior suspended hemophilia programs.
